AB0331 Incidence of malignancy in psoriatic and rheumatoid arthritis patients living in newfoundland and labrador
Authors: A.F. Lewis, I. Landells, G. Mugford, M. Khraishi
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) are reported to be associated with an increased risk of malignancy. Newfoundland and Labrador (NL) has one of the highest cancer rates in Canada. There is a paucity of literature on the prevalence of malignancy in NL patients with PsA and RA. <h3>Objectives</h3> Evaluate the incidence of malignancy in a cohort of PsA and RA patients and compare rates with the general population. Evaluate the impact of therapy of these two diseases. <h3>Methods</h3> Data was extracted from the charts of- 200 PsA and 500 RA patients seen at a rheumatology clinic in St. John's between 2011 and 2014. Statistical analyses were performed using SPSS version 21.0 for Windows (IBM Inc.). Person-time Rate (PYs) per 100,000, stratified by age and gender, were used to estimate overall cancer risk and proportions between the two cohorts. Observed rates were compared with Statistics Canada reported general NL rates. <h3>Results</h3> We identified 37 (5.3%)malignancies;- 34 (91.8%) solid and 3 (8.1%) hematologic. Mean (SD) age was 58.4 (12.28) and age at diagnoses of disease was 46.8 (12.88). Four hundred and eighty (68.6%) were females. No difference was observed in rates between the study population and the NL general population (p&lt;0.3217). The most common solid tumours were breast 8 (21.6%) and skin 8 (21.6%), followed by five bowel and lung cancers in equal proportions (13.5%). Distribution of cancers between the two cohorts were similar. <h3>Conclusions</h3> The results suggests there is no difference in the cancer rate between our cohorts and the NL general population. We acknowledge study limitations related to shorter duration of follow-up and lower sample size. <h3>References</h3> [1] Abásolo L, Júdez E, Descalzo MÁ, et al. Cancer in rheumatoid arthritis: Occurrence, mortality, and associated factors in a southEuropean population2008;37(6):388–3974. [2] Chen Y, Chang Y, Wang C, Wu C. The risk of cancer in patients with rheumatoid arthritis: A nationwide cohort study in Taiwan. Arthritis &amp; Rheumatology2011;63(2):352–358. [3] Gross RL, Schwartzman-Morris JS, Krathen M, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis &amp; Rheumatology2014;66(6):1472–1481. [4] Khraishi, Majed, et al. Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts."Clinical rheumatology2011;30(7):877–885. [5] Khraishi M, Landells I, Mugford G. The self-administered psoriasis and arthritis screening questionnaire (PASQ): A sensitive and specific tool for the diagnosis of early and established psoriatic arthritis2010;16(2):9–16. [6] Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD. Prevalence of malignancy in psoriatic arthritis. Arthritis &amp; Rheumatology2008;58(1):82–87. [7] Statistics Canada. https://www.statcan.gc.caDisclosure of Interest: None declared